Immatics (NASDAQ:IMTX – Get Rating) saw a significant increase in short interest in September. As of September 15th, there was short interest totalling 3,160,000 shares, an increase of 9.7% from the August 31st total of 2,880,000 shares. Approximately 6.8% of the shares of the company are short sold. Based on an average trading volume of 266,500 shares, the days-to-cover ratio is currently 11.9 days.
Immatics Price Performance
IMTX stock traded up $0.23 during trading on Monday, hitting $10.23. 2,014 shares of the company traded hands, compared to its average volume of 191,581. The stock’s 50-day simple moving average is $11.33 and its 200 day simple moving average is $9.22. The company has a market cap of $643.56 million, a PE ratio of 20.83, a P/E/G ratio of 2.76 and a beta of 0.44. Immatics has a 1 year low of $5.75 and a 1 year high of $14.90.
Immatics (NASDAQ:IMTX – Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of $0.13 by ($0.36). Immatics had a net margin of 18.88% and a return on equity of 36.11%. The business had revenue of $18.19 million during the quarter, compared to analyst estimates of $42.27 million. Research analysts expect that Immatics will post 0.37 earnings per share for the current year.
Institutional Trading of Immatics
Institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Immatics in the first quarter valued at approximately $27,000. Wolverine Asset Management LLC acquired a new stake in Immatics in the second quarter valued at approximately $42,000. UBS Group AG grew its holdings in Immatics by 230.3% in the second quarter. UBS Group AG now owns 5,862 shares of the company’s stock valued at $51,000 after purchasing an additional 4,087 shares during the period. Lazard Asset Management LLC acquired a new stake in Immatics in the first quarter valued at approximately $84,000. Finally, Trexquant Investment LP acquired a new stake in Immatics in the second quarter valued at approximately $98,000. 34.12% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Chardan Capital reduced their price target on Immatics from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, August 10th.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immatics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Immatics wasn’t on the list.
While Immatics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Short Interest in Immatics (NASDAQ:IMTX) Increases By 9.7%